Streetbeat News

Products Services

ETON

CROSSJECT has enhanced its collaboration with Eton Pharmaceuticals to develop a proprietary hydrocortisone formulation (ET-800) for the US hospital adrenal insufficiency market. The partnership involves CROSSJECT providing an innovative, ready-to-use liquid formulation that simplifies injection compared to current solutions. CROSSJECT will earn a high single-digit royalty on Eton's net sales, with product filings expected from the second half of 2026.

Portfolio Pulse from

March 25, 2025 | 6:45 am

NVS

Novartis will present comprehensive seven-year disability outcomes and safety data for Kesimpta® at the American Academy of Neurology Annual Meeting in San Diego. The presentations will cover long-term treatment results in relapsing multiple sclerosis patients, including continuous treatment safety profiles and efficacy across different disease stages.

Portfolio Pulse from

March 25, 2025 | 6:30 am

NVS

Novartis will present comprehensive seven-year disability outcomes and safety data for Kesimpta® at the American Academy of Neurology Annual Meeting in San Diego. The presentations will cover long-term treatment results in relapsing multiple sclerosis patients, including continuous treatment safety profiles and efficacy across different disease stages.

Portfolio Pulse from

March 25, 2025 | 6:30 am

SNY

Sanofi has received priority review from the FDA for tolebrutinib, a potential breakthrough therapy for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The drug is unique in its ability to cross the blood-brain barrier and target smoldering neuroinflammation, which could potentially slow disability progression. The target action date for FDA decision is September 28, 2025.

Portfolio Pulse from

March 25, 2025 | 6:15 am

SNY

Sanofi has received priority review from the FDA for tolebrutinib, a potential breakthrough therapy for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The drug is unique in its ability to cross the blood-brain barrier and target smoldering neuroinflammation, which could potentially slow disability progression. The target FDA decision date is September 28, 2025.

Portfolio Pulse from

March 25, 2025 | 6:15 am

IGT

International Game Technology (IGT) is strategically returning to its core lottery business, emphasizing its strength in selling lottery systems and technology. The company appears to be repositioning itself by focusing on its most profitable segment, which involves providing lottery infrastructure and technology solutions.

Portfolio Pulse from

March 25, 2025 | 5:45 am

BYDDY

Michael Dunne, CEO of Dunne Insights, highlighted BYD's remarkable performance, describing the company's growth as the most 'explosive' in automotive industry history over the past 100 years. The analysis focuses on BYD's latest earnings and emerging technological innovations, signaling strong momentum in the electric vehicle sector.

Portfolio Pulse from

March 25, 2025 | 5:30 am

COIN

Circle is launching USDC in Japan on March 26 via a partnership with SBI Holdings, following regulatory approval from the Japan Financial Services Agency. This move represents a strategic expansion into a key Asian market with strong blockchain technology adoption, potentially increasing USDC's global reach and transaction volume.

Portfolio Pulse from

March 25, 2025 | 5:30 am

ALC

Alcon has received CE Mark approval for its Clareon Vivity intraocular lens (IOL) in Europe, marking a significant advancement in cataract surgery technology. The lens offers extended depth of focus, reduces patients' dependence on glasses, and provides high patient satisfaction rates of over 90%. It is designed to address vision needs for patients with various eye conditions and is available on Alcon's most advanced lens material, Clareon.

Portfolio Pulse from

March 25, 2025 | 5:15 am

ALC

Alcon has received CE Mark approval for its Clareon Vivity intraocular lens (IOL) in Europe, marking a significant advancement in cataract surgery technology. The lens offers extended depth of focus, reduces patients' dependence on glasses, and provides high patient satisfaction rates of over 90%. It is designed to address vision needs for patients with various eye conditions and is available on Alcon's most advanced lens material.

Portfolio Pulse from

March 25, 2025 | 5:15 am